Roquefort Therapeutics (LSE:ROQ) FCF Margin % : 0.00% (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Roquefort Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Roquefort Therapeutics's Free Cash Flow for the six months ended in Jun. 2024 was £-0.53 Mil. Roquefort Therapeutics's Revenue for the six months ended in Jun. 2024 was £0.00 Mil. Therefore, Roquefort Therapeutics's FCF Margin % for the quarter that ended in Jun. 2024 was 0.00%.

As of today, Roquefort Therapeutics's current FCF Yield % is -23.86%.

The historical rank and industry rank for Roquefort Therapeutics's FCF Margin % or its related term are showing as below:

LSE:ROQ' s FCF Margin % Range Over the Past 10 Years
Min: -894 Med: -894 Max: -685
Current: -685

During the past 3 years, the highest FCF Margin % of Roquefort Therapeutics was -685.00%. The lowest was -894.00%. And the median was -894.00%.

LSE:ROQ's FCF Margin % is ranked worse than
70.24% of 1045 companies
in the Biotechnology industry
Industry Median: -145.32 vs LSE:ROQ: -685.00

Roquefort Therapeutics FCF Margin % Historical Data

The historical data trend for Roquefort Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roquefort Therapeutics FCF Margin % Chart

Roquefort Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

FCF Margin %

-894.00

Roquefort Therapeutics Semi-Annual Data
	Jun21	Jun22	Dec22	Jun23	Dec23	Jun24
FCF Margin %	Get a 7-Day Free Trial			-	-	-471.50	-	-

Competitive Comparison of Roquefort Therapeutics's FCF Margin %

For the Biotechnology subindustry, Roquefort Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Roquefort Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Roquefort Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Roquefort Therapeutics's FCF Margin % falls into.

Roquefort Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Roquefort Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-1.788	/	0.2
	=	-894.00 %

Roquefort Therapeutics's FCF Margin for the quarter that ended in Jun. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jun. 2024 )	/	Revenue (Q: Jun. 2024 )
	=	-0.525	/	0
	=	%

Roquefort Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Roquefort Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Roquefort Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Roquefort Therapeutics PLC (LSE:ROQ) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

ROQAF:USA

Address

85 Great Portland Street, First Floor, London, GBR, W1W 7LT

Website

https://www.roquefortplc.com

Roquefort Therapeutics PLC is engaged in pursuing opportunities to acquire medical biotechnology businesses. Its product portfolio consists of MDK Antibody, MDK Oligo, MDK mRNA, STAT-6 siRNA, and MK Cell. The principal activity of the Company is to develop pre-clinical next-generation medicines focused on hard-to-treat cancers.

Roquefort Therapeutics Headlines

No Headlines